{
    "clinical_study": {
        "@rank": "23395", 
        "arm_group": [
            {
                "arm_group_label": "Udenafil", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Bosentan", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Udenafil/Bosentan", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to investigate the pharmacokinetic drug interaction and safety after\n      oral administration of Udenafil(DA-8159) and Bosentan in healthy volunteers.\n\n      Design: Randomized, open-label, multiple-dose, three-treatment, three-period, six-sequence,\n      Williams design\n\n      Investigational Product: Udenafil, Bosentan"
        }, 
        "brief_title": "Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Bosentan After Oral Administration", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  healthy volunteers between the ages of 20 to 45 years old within the range of BMI\n             between 18.5 and 25(Body Mass Index)\n\n          -  having neither congenital/chronic diseases nor pathological symptoms/findings as\n             results of medical examination\n\n          -  doctor determines to be suitable as subjects within 4 weeks ago before administration\n\n        Exclusion Criteria:\n\n          -  Hypersensitivity(or history of hypersensitivity) to Udenafil, Bosentan and PDE5\n             inhibitors\n\n          -  Active Liver Diseases or exceed 1.25 times the normal range of AST, ALT\n\n          -  Gastrointestinal diseases or surgeries that affect absorption of drug\n\n          -  Excessive drinking(exceed 210g/week) and excessive caffeine(exceed 5cups/day)\n\n          -  Smoking over 10 cigarettes per day\n\n          -  pregnant or nursing female volunteers"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01929213", 
            "org_study_id": "DA8159_PAH_DI"
        }, 
        "intervention": [
            {
                "arm_group_label": "Udenafil", 
                "description": "Udenafil is administered", 
                "intervention_name": "Udenafil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Bosentan", 
                "description": "Bosentan is administered", 
                "intervention_name": "Bosentan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Udenafil/Bosentan", 
                "description": "Udenafil and Bosentan are administered", 
                "intervention_name": "Udenafil/Bosentan", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bosentan", 
                "Udenafil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Severance Hospital Clinical Trial Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Open-label, Multiple Dose, Three-treatment, Three-period, Six-sequence Williams Design to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Bosentan After Oral Administration in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Severance Hospital", 
            "last_name": "Min Soo Park", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Udenafil, Bosentan C max,ss", 
                "safety_issue": "No", 
                "time_frame": "Blood gathering point: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12h of D1, D15, D29(if Udenafil adminstrated alone), 0 h of D7, D21, D35, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36 h of D8, D22, D36"
            }, 
            {
                "measure": "Udenafil, Bosentan AUC tau,ss", 
                "safety_issue": "No", 
                "time_frame": "Blood gathering point: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12h of D1, D15, D29(if Udenafil adminstrated alone), 0 h of D7, D21, D35, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36 h of D8, D22, D36"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01929213"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Dong-A ST Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}